Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV Platform into High Consequence Global Health Threats Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV Platform into High Consequence Global Health Threats...

Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors PR Newswire CAMBRIDGE, Mass., July 15, 2026 CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a...

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday's regular session. The company's market cap stands at $1.9 million. Decoy Therapeutics (NASDAQ:DCOY) sharesread more...

Decoy Therapeutics has secured funding to begin clinical trials for its programs targeting respiratory illnesses.

Decoy Therapeutics (NASDAQ:DCOY) announced a private investment in public equity (PIPE) financing that could provide the biotechnology company with up to approximately $21 million in gross proceeds through a combination of upfront funding and milestone-based warrant exercises. The initial closing is expected to generate approximately $3.5 million, with additional capital becoming available if specified clinical, regulatory, and shareholder approval milestones are achieved. The company said it intends to use the proceeds to advance its lead antiviral candidate into clinical trials.

As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. $UPC, $NTHI, $DCOY, $VRDN

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 159.6% to $7.68 during Monday's pre-market session. The company's market cap stands at $1.9 million. Decoy Therapeutics (NASDAQ:DCOY) stockread more...

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing PR Newswire HOUSTON, June 26, 2026 HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or...

Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London PR Newswire CAMBRIDGE, Mass., June 8, 2026 Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for...